BARDROFF, Michael Otto,BRANNETTI, Barbara,CAMPBELL, Emma Michelle,DIEFENBACH-STREIBER, Beate,EBERTH, Adina,KUNZ, Christian Carsten Silvester,MARSHALL, Sylwia,RONDEAU, Jean-Michel Rene,SCHLAEPPI, Jean-
申请号：
AU2020201556
公开号：
AU2020201556A1
申请日:
2020.03.03
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020201556A120200319.pdf#####I: Interwovn NRPortbl DCC SZP 19939092_I.docx-3/03/2020 ABSTRACT IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
